About us

Epiphany Biosciences, Inc. is a late-stage biotechnology company committed to the development of novel antiviral therapeutics for diseases of viral origin in areas of unmet medical need. To support this mission, Epiphany has assembled an experienced team of virologists, clinicians, and drug development experts.

More about Epiphany >>

About Valomaciclovir Stearate (EPB-348)

EPB-348 is a small molecule drug with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus ("EBV", the first virus to be directly associated with human cancer) and varicella zoster virus (the cause of shingles). EPB-348 is being developed as the first antiviral for EBV with a particular focus on management of EBV viremia in organ transplant recipients. EPB-348 is also being evaluated as as the first antiviral for shingles with an impact on zoster associated pain.

More about EBV Transplant Infection >>
More about Shingles >> 
More about EPB-348 >>


Contact  |  Site Map

Copyright 2009-2014 Epiphany Biosciences, Inc.